Hjem › Tripelnegativ brystkreft › Georgia › Atlanta
Kliniske studier for Tripelnegativ brystkreft i Atlanta, GA
20 studier for Tripelnegativ brystkreft søker deltakere på steder i og rundt Atlanta (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
RekruttererFase 1
- Winship Cancer Institute of Emory University, Atlanta
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RekruttererFase 1
- Emory University, Atlanta
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
RekruttererFase 1
- Emory Winship Cancer Institute, Atlanta
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
RekruttererFase 2
- Emory University (Data Collection Only), Atlanta
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
RekruttererFase 3
- Piedmont Cancer Institute, Atlanta
- Northside Hospital, Atlanta
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
RekruttererFase 1
- Emory University, Atlanta
Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
RekruttererFase 2
- Emory University, Atlanta
ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
RekruttererFase 1/2
- Emory University Winship Cancer Institute, Atlanta
- Winship Cancer Institute of Emory University, Atlanta
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
RekruttererFase 2/3
- Northside Hospital, Atlanta
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
RekruttererFase 1/2
- Winship Cancer Institute, Emory University, Atlanta
Study of XB010 in Subjects With Solid Tumors
RekruttererFase 1
- Winship Cancer Institute, Atlanta
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
RekruttererFase 1
- Winship Cancer Institute / Emory University, Atlanta
Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer
RekruttererFase 2
- Emory University Hospital, Atlanta
Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- Emory University/Winship Cancer Institute, Atlanta
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RekruttererFase 2
- Winship Cancer Institute of Emory University, Atlanta
High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
RekruttererFase 2
- Emory University Hospital/Winship Cancer Institute, Atlanta
Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
RekruttererFase 1
- Emory University, Winship Cancer Institute, Atlanta
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
RekruttererFase 1/2
- Winship Cancer Institute - Emory University, Atlanta
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
RekruttererFase 1
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- og 1 flere
A Beta-only IL-2 ImmunoTherapY Study
RekruttererFase 1/2
- Emory - Winship Cancer Institute, Atlanta
Tripelnegativ brystkreft-studier i andre byer
- Houston, TX42 studier
- New York City, NY31 studier
- Nashville, TN28 studier
- Los Angeles, CA27 studier
- Boston, MA26 studier
- San Antonio, TX23 studier
- St. Louis, MO21 studier
- Arlington, VA20 studier
- Dallas, TX18 studier
- Chicago, IL16 studier
- Columbus, OH16 studier
- Grand Rapids, MI15 studier
Andre studier i Atlanta
- Kreft (alle typer)49 studier
- Ikke-småcellet lungekreft47 studier
- Multipelt myelom42 studier
- Brystkreft41 studier
- Prostatakreft33 studier
- Akut myelogen leukemi31 studier
- Eggstokkreft29 studier
- Kolorektal kreft29 studier
- Lungekreft29 studier
- Metastatisk kreft28 studier
- Major depresjon25 studier
- Hjertesvikt25 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.